1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can ...
The cobas smart e immunoanalyser – the newest addition to Roche’s industry-leading cobas immunoassay systems portfolio – is ...
Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the strategic ...
Following the reverse split, every ten (10) shares of Onconetix common stock will be automatically exchanged into one share ...
Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.
Since 2025, U.S. biopharma companies have raised $37.2 billion—68% of total worldwide venture capital funding—with startups ...
Company strengthens commercial leadership to scale AI deployments as wet laboratories face growing demand from AI-driven drug ...
Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial ...
MustGrow recently announced the receipt of its first development milestone payment Bayer, part of their License and ...
The Company will initiate its planned clinical study of BIO 300 Injectable Suspension, subject to Institutional Review Board ...
October 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and ...
AM ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results